Elon Musk says Neuralink will scale implants and automate brain surgery by 2026. The claim raises questions about how invasive BCIs fit clinical, financial, and patient realities.

Researchers at Columbia and partners unveiled BISC, a paper-thin subdural neural chip with 65,536 electrodes and wireless data transfer, signaling a shift toward fully integrated, high-density BCI hardware.

A Russian startup’s brain-implanted pigeons expose how neurotechnology can slip from research into ethically ambiguous uses when oversight is weak and incentives favour control over care.

Phantom Neuro is advancing implantable muscle interfaces that improve prosthetic hand control, targeting one of neurotech’s clearest paths to real-world adoption and near-term clinical impact.

Brain-computer interfaces are entering regulated human trials across invasive, minimally invasive, and non-invasive approaches, signalling a shift from experimental demos to real clinical pipelines.

Given this mix of acceleration and backlash, it’s worth asking a simple question: are BCIs still overhyped, and if so, where exactly is the gap between story and reality?

An MIT-led team demonstrated surgery-free neuromodulation using sub-cellular chips carried by immune cells into the brain, where near-infrared light wirelessly activates local neural circuits.

Serial neurotech founder Hamed Bahmani has unveiled Insellar, a stealth startup exploring deep-brain stimulation of neuroendocrine systems as a new approach to treating severe, treatment-resistant depression.

INBRAIN has teamed up with Microsoft to combine graphene BCIs with agentic AI on Azure, aiming to build adaptive, closed-loop neurotherapies that learn from each patient’s brain signals in real time.

Capital is concentrating around six invasive BCI leaders as investors back platforms with repeatable surgery, stable signals, and clear regulatory paths. The field is shifting from proof-of-concept to execution.

Tech billionaires are flooding into neurotech, backing brain-computer interfaces across invasive and non-invasive approaches. Their capital is accelerating progress while raising questions about control, incentives, and who shapes this technology.

Neuralink’s first UK implant shows its intracortical BCI can be deployed inside the NHS with rapid, functional control.

Coherence Neuro is advancing an implantable BCI that uses electrical stimulation and sensing to disrupt tumor activity and monitor brain cancer in real time.

The PRIMA retinal implant demonstrates clinically validated restoration of functional vision in advanced macular degeneration, marking a major milestone for sensory BCIs.

uCat is developing a software layer that turns high-bandwidth BCI signals into speech and embodied interaction, using virtual environments to restore agency and enable richer forms of communication and control.

A university hospital in Munich has completed Europe’s first intracortical BCI implant in a patient with quadriplegia, reflecting a clinic-first model focused on safety, rehabilitation, and healthcare-system readiness rather than speed or publicity.

Neuralink has leased a large life-science facility in South San Francisco, signaling a renewed Bay Area presence as the company moves from early human trials toward clinical scale-up and operational maturity.

Subsense is developing a nanoparticle-based brain-computer interface delivered through the nose, aiming to modulate brain activity without surgery and reduce reliance on implanted electrodes.

Graphene-based brain–computer interfaces are moving out of the lab and into U.S. clinical pathways, as INBRAIN partners with Mayo Clinic to validate a new materials-driven approach to neuromodulation.

Many amputees abandon advanced prosthetics because control is unintuitive or invasive. A new startup is rethinking bionic limbs around non-invasive brain signals, affordability, and everyday usability.

By pairing EEG with an AI copilot, researchers show how shared autonomy can turn noisy brain signals into reliable control, narrowing the long-standing gap between non-invasive and implanted brain–computer interfaces.

A new generation of neurotech founders is emerging earlier than ever. With personal stakes and a DIY mindset, a student-led team is applying brain–computer interfaces to one of epilepsy’s most persistent challenges.

A new brain–computer interface can decode silently imagined sentences in real time. For people with paralysis, inner speech offers a faster, less fatiguing, and more natural path to communication.

A new entrant is forming in the brain–computer interface space with unusually deep capital, strong AI ties, and ambitions that may extend beyond medicine, adding a fresh dynamic to an already competitive neurotech field.

A new generation of brain–computer interfaces is emerging with a different philosophy: minimise invasiveness, prioritise safety, and fit real clinical workflows. Precision Neuroscience exemplifies this shift toward practical neurotechnology.